Leeds Institute of Rheumatic and Musculoskeletal Medicine, St James's University Hospital, Leeds, UK.
Institute of Microbiology and Infection, University of Birmingham, Birmingham, UK.
J Clin Immunol. 2022 Jan;42(1):158-170. doi: 10.1007/s10875-021-01161-w. Epub 2021 Oct 21.
The NLRP3 inflammasome is a vital mediator of innate immune responses. There are numerous NLRP3 mutations that cause NLRP3-associated autoinflammatory diseases (NLRP3-AIDs), mostly in or around the NACHT domain. Here, we present a patient with a rare leucine-rich repeat (LRR) domain mutation, p.Arg920Gln (p.R920Q), associated with an atypical NLRP3-AID with recurrent episodes of sore throat and extensive oropharyngeal ulceration. Unlike previously reported patients, who responded well to anakinra, her oral ulcers did not significantly improve until the PDE4 inhibitor, apremilast, was added to her treatment regimen. Here, we show that this mutation enhances interactions between NLRP3 and its endogenous inhibitor, NIMA-related kinase 7 (NEK7), by affecting charge complementarity between the two proteins. We also demonstrate that additional inflammatory mediators, including the NF-кB and IL-17 signalling pathways and IL-8 chemokine, are upregulated in the patient's macrophages and may be directly involved in disease pathogenesis. These results highlight the role of the NLRP3 LRR domain in NLRP3-AIDs and demonstrate that the p.R920Q mutation can cause diverse phenotypes between families.
NLRP3 炎性小体是先天免疫反应的重要介质。有许多 NLRP3 突变导致 NLRP3 相关自身炎症性疾病(NLRP3-AIDs),这些突变主要发生在 NACHT 结构域内或附近。在这里,我们报告了一例罕见的富含亮氨酸重复(LRR)结构域突变 p.Arg920Gln(p.R920Q)与一种不典型的 NLRP3-AID 相关,其特征是反复出现咽痛和广泛的口咽溃疡。与以前报道的对 anakinra 反应良好的患者不同,直到将 PDE4 抑制剂阿普司特加入她的治疗方案中,她的口腔溃疡才明显改善。在这里,我们表明该突变通过影响两种蛋白质之间的电荷互补性,增强了 NLRP3 与其内源性抑制剂 NIMA 相关激酶 7(NEK7)之间的相互作用。我们还证明,包括 NF-κB 和 IL-17 信号通路以及 IL-8 趋化因子在内的其他炎症介质在患者的巨噬细胞中被上调,并且可能直接参与疾病发病机制。这些结果强调了 NLRP3 LRR 结构域在 NLRP3-AIDs 中的作用,并表明 p.R920Q 突变可导致家族之间出现不同的表型。